CTXR Stock Analysis: Buy, Sell, or Hold?
CTXR - Citius Pharmaceuticals Inc. Common
$0.57
-0.03 (-4.93%)
âŧ
5d:
+1.53%
30d:
+9.67%
90d:
-18.61%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 18, 2026
0d
Get Alerted When CTXR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: CTXR is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: CTXR is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: CTXR is currently trading at $0.57, which is considered fair relative to its 30-day fair value range of $0.51 to $0.69. From a valuation perspective, the stock is trading at a discount (Forward PE: -0.4) compared to its historical average (0.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, CTXR is in a downtrend. Immediate support is located at $0.55, while resistance sits at $0.79. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: CTXR scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+566.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CTXR is in a downtrend. Immediate support is located at $0.55, while resistance sits at $0.79. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: CTXR scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.00 (+566.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.51 -
$0.69
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.9%)
- BULLISH: Trading 566.4% below Wall St target ($4.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 39/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.51 -
$0.69
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.55
Resistance Level
$0.79
Current Trend
Downtrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.42
Wall Street Target
$4.00
(+566.4%)
PE vs Historical
-0.4 vs 0.3
CHEAP
Share & Embed Analysis
Last updated: August 24, 2026 2:07 PM ET
Data refreshes hourly during market hours. Next update: 3:07 PM
Data refreshes hourly during market hours. Next update: 3:07 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CTXR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 39 SELL |
|
REGN
Regeneron PharmaceuticalâĻ |
STRONG BUY
25 analysts |
$840 | 40 SELL |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$281 | 62 BUY |
|
MLTX
MoonLake ImmunotherapeutâĻ |
STRONG BUY
16 analysts |
$29 | 48 HOLD |
|
ACAD
ACADIA Pharmaceuticals IâĻ |
BUY
20 analysts |
$34 | 47 HOLD |
